Phase III trial comparing dexamethasone (DEX) to the combination of DEX + CC-5013 in patients with previously untreated multiple myeloma.

Trial Profile

Phase III trial comparing dexamethasone (DEX) to the combination of DEX + CC-5013 in patients with previously untreated multiple myeloma.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2015

At a glance

  • Drugs Lenalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Nov 2010 Primary endpoint 'Progression-free-survival-rate' has been met
    • 24 Nov 2010 Status changed from active, no longer recruiting to completed.
    • 27 Sep 2010 Results were published in Blood.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top